A Dark Vector Cognition product

Vertex Pharmaceuticals 10-Q 2026-09-30

VRTX · CIK 875320 · Form 10-Q · Period ended September 30, 2026 · Filed November 3, 2026

Revenue rose 11.8% to $3.44 billion. Operating margin was 20.7%, against 38.6% a year earlier. Net income was $654 million.

8 sections, 157K characters. Original on sec.gov · ·

Risk FactorsBusiness

Key numbers
MeasureQuarter ended Sep 30, 2026Quarter ended Sep 30, 2025Change
Revenue$3.44B$3.08B+11.8%
Operating income$713M$1.19B-39.9%
Net income$654M$1.08B-39.6%
Diluted EPS$2.56$4.20-39.0%
Cash and equivalents$4.98Bn/an/a
Operating margin*20.7%38.6%-17.8 pts

From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.

The 51 tables in this filing as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Cover and table of contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2026

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

Commission file number 000-19319

____________________________________________

Vertex Pharmaceuticals Incorporated

(Exact name of registrant as specified in its charter)

Massachusetts

(State or other jurisdiction of incorporation or organization)

50 Northern Avenue**,** Boston**,** Massachusetts

(Address of principal executive offices)

04-3039129

(I.R.S. Employer Identification No.)

02210

(Zip Code)

Registrant’s telephone number, including area code (617) 341-6100


Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.01 Par Value Per ShareVRTXThe Nasdaq Global Select Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities

Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and

(2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to

Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was

required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting

company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting

company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Common Stock, par value $0.01 per share253,537,674Outstanding at October 31, 2026

VERTEX PHARMACEUTICALS INCORPORATED

FORM 10-Q

FOR THE QUARTER ENDED SEPTEMBER 30, 2026

TABLE OF CONTENTS

Page
Part I. Financial Information
Item 1.Financial Statements (unaudited)2
Condensed Consolidated Statements of Income2
Condensed Consolidated Statements of Comprehensive Income3
Condensed Consolidated Balance Sheets4
Condensed Consolidated Statements of Shareholders' Equity5
Condensed Consolidated Statements of Cash Flows6
Notes to Condensed Consolidated Financial Statements7
Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations24
Item 3.Quantitative and Qualitative Disclosures About Market Risk37
Item 4.Controls and Procedures37
Part II. Other Information
Item 1.Legal Proceedings37
Item 1A.Risk Factors37
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds39
Item 5.Other Information39
Item 6.Exhibits41
Signatures42

“Vertex,” “we,” “us,”, “our” and the “Company” as used in this Quarterly Report on Form 10-Q refer to Vertex

Pharmaceuticals Incorporated, a Massachusetts corporation, and its subsidiaries.

“Vertex®,” “KALYDECO®,” “ORKAMBI®,” “SYMDEKO®,” “SYMKEVI®,” “TRIKAFTA®,” “KAFTRIO®,”

“CASGEVY®,” “ALYFTREK®,” and “JOURNAVX®” are registered trademarks of Vertex. “PALSONIFY®” is a registered

trademark of Crinetics Pharmaceuticals, Inc., a wholly owned subsidiary of Vertex. Other brands, names and trademarks

contained in this Quarterly Report on Form 10-Q are the property of their respective owners.

We use the brand name for our products when we refer to the product that has been approved and with respect to the

indications on the approved label. Otherwise, including in discussions of our cystic fibrosis, sickle cell disease, beta

thalassemia, and pain development programs, we refer to our product candidates by their scientific (or generic) name or VX

developmental designation.

Part I. Financial Information

Item 1. Financial Statements

VERTEX PHARMACEUTICALS INCORPORATED

Condensed Consolidated Statements of Income

(unaudited; in millions, except per share amounts)

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenues:
Product revenues, net$3,440.8$3,076.4$9,761.6$8,780.6
Other revenues———30.7
Total revenues3,440.83,076.49,761.68,811.3
Costs and expenses:
Cost of sales526.1414.81,408.11,185.3
Research and development expenses1,320.6977.73,276.02,935.8
Acquired in-process research and development expenses40.654.562.576.5
Selling, general and administrative expenses844.1445.11,920.01,266.1
Intangible asset impairment charge———379.0
Change in fair value of contingent consideration(3.5)(1.9)(2.9)1.2
Total costs and expenses2,727.91,890.26,663.75,843.9
Income from operations712.91,186.23,097.92,967.4
Interest income118.4125.7360.1369.0
Interest expense(36.0)(3.3)(42.3)(10.0)
Other (expense) income, net(11.9)(9.8)12.4(14.2)
Income before provision for income taxes783.41,298.83,428.13,312.2
Provision for income taxes129.8215.9643.3550.1
Net income$653.6$1,082.9$2,784.8$2,762.1
Net income per common share:
Basic$2.58$4.24$10.98$10.77
Diluted$2.56$4.20$10.90$10.68
Shares used in per share calculations:
Basic253.5255.6253.7256.4
Diluted255.2257.6255.5258.6

The accompanying notes are an integral part of these condensed consolidated financial statements.

VERTEX PHARMACEUTICALS INCORPORATED

Condensed Consolidated Statements of Comprehensive Income

(unaudited; in millions)

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Net income$653.6$1,082.9$2,784.8$2,762.1
Other comprehensive income (loss):
Unrealized holding (losses) gains on available-for-sale debt securities, net of tax of $7.0, $(1.0), $20.7 and $(7.7), respectively(24.8)3.5(73.4)27.4
Unrealized gains (losses) on foreign currency forward contracts, net of tax of $(10.7), $(9.4), $(45.8) and $70.3, respectively38.233.5162.8(248.7)
Foreign currency translation adjustment(4.7)(0.4)(16.3)29.0
Total other comprehensive income (loss)8.736.673.1(192.3)
Comprehensive income$662.3$1,119.5$2,857.9$2,569.8

The accompanying notes are an integral part of these condensed consolidated financial statements.

VERTEX PHARMACEUTICALS INCORPORATED

Condensed Consolidated Balance Sheets

(unaudited; in millions, except share and per share data)

September 30, 2026December 31, 2025
Assets
Current assets:
Cash and cash equivalents$4,979.3$5,084.8
Marketable securities1,324.01,523.3
Accounts receivable, net2,311.02,052.8
Inventories2,245.31,686.8
Prepaid expenses and other current assets826.7853.3
Total current assets11,686.311,201.0
Property and equipment, net1,711.51,520.3
Goodwill2,423.41,088.0
Other intangible assets, net8,517.8424.2
Deferred tax assets1,952.92,897.9
Operating lease assets1,617.21,562.7
Long-term marketable securities3,517.95,712.3
Other assets1,309.31,236.6
Total assets$32,736.3$25,643.0
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable$472.6$461.7
Accrued expenses3,235.12,971.2
Short-term debt999.6—
Other current liabilities293.0428.3
Total current liabilities5,000.33,861.2
Long-term debt3,497.0—
Long-term operating lease liabilities1,981.81,846.5
Other long-term liabilities1,349.81,269.5
Total liabilities11,828.96,977.2
Commitments and contingencies (Note M)
Shareholders’ equity:
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued——
Common stock, $0.01 par value; 500,000,000 shares authorized, 253,522,595 and 253,991,224 shares issued and outstanding, respectively2.52.5
Additional paid-in capital4,502.95,119.2
Accumulated other comprehensive income (loss)57.2(15.9)
Retained earnings16,344.813,560.0
Total shareholders’ equity20,907.418,665.8
Total liabilities and shareholders’ equity$32,736.3$25,643.0

The accompanying notes are an integral part of these condensed consolidated financial statements.

VERTEX PHARMACEUTICALS INCORPORATED

Condensed Consolidated Statements of Shareholders’ Equity

(unaudited; in millions)

Three Months Ended
Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive Income (Loss)Retained EarningsTotal Shareholders’ Equity
SharesAmount
Balance at June 30, 2025256.3$2.6$5,987.9$(101.1)$11,286.0$17,175.4
Other comprehensive income, net of tax———36.6—36.6
Net income————1,082.91,082.9
Repurchases of common stock(2.7)(0.1)(1,092.4)——(1,092.5)
Common stock withheld for employee tax obligations(0.2)—(91.0)——(91.0)
Issuance of common stock under benefit plans0.6—8.1——8.1
Stock-based compensation expense——199.3——199.3
Balance at September 30, 2025254.0$2.5$5,011.9$(64.5)$12,368.9$17,318.8
Balance at June 30, 2026253.3$2.5$4,505.7$48.5$15,691.2$20,247.9
Other comprehensive income, net of tax———8.7—8.7
Net income————653.6653.6
Repurchases of common stock(0.2)—(120.8)——(120.8)
Common stock withheld for employee tax obligations(0.2)—(79.3)——(79.3)
Issuance of common stock under benefit plans0.6—19.8——19.8
Stock-based compensation expense——177.5——177.5
Balance at September 30, 2026253.5$2.5$4,502.9$57.2$16,344.8$20,907.4
Nine Months Ended
Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive Income (Loss)Retained **

Showing the first 8K of 80K characters. Open the full section

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

OVERVIEW

We are a global biotechnology company that invests in scientific innovation to create transformative medicines for

people with serious diseases, with a focus on specialty markets. We have eight approved medicines: five that treat the

underlying cause of cystic fibrosis (“CF”), a life-threatening genetic disease, one that treats severe sickle cell disease

(“SCD”) and transfusion dependent beta thalassemia (“TDT”), life shortening inherited blood disorders, one that treats

moderate-to-severe acute pain, and one that treats acromegaly. We are also preparing for the anticipated launch of

povetacicept, a potential treatment for IgA nephropathy (“IgAN”). Our clinical-stage pipeline spans a range of programs

targeting CF, SCD, beta thalassemia, IgAN, neuropathic pain, APOL1-mediated kidney disease, primary membranous

nephropathy, congenital adrenal hyperplasia, adrenocorticotropic hormone-dependent Cushing’s syndrome, autosomal

dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis and myotonic dystrophy type 1, reflecting

our commitment to addressing significant unmet medical needs globally.

Financial Highlights

Total RevenuesIn the third quarter of 2026, our total revenues increased to $3.4 billion as compared to $3.1 billion in the third quarter of 2025, primarily due to continued performance of our CF therapies and growth from diversification into additional disease areas.
Cost of SalesOur cost of sales as a percentage of our net product revenues increased to 15.3% in the third quarter of 2026 as compared to 13.5% in the third quarter of 2025, as a result of changes in product mix and increased intangible asset amortization expense resulting from our acquisition of Crinetics Pharmaceuticals, Inc. (“Crinetics”) in the third quarter of 2026 (the “Crinetics Acquisition”), partially offset by a lower blended royalty rate for our CF medicines.
Total R&D, AIPR&D and SG&A ExpensesOur total research and development (“R&D”), acquired in-process research and development expenses (“AIPR&D”) and selling, general and administrative (“SG&A”) expenses increased to $2.2 billion in the third quarter of 2026 as compared to $1.5 billion in the third quarter of 2025, primarily due to approximately $500.0 million of compensation and transaction expenses associated with the Crinetics Acquisition.
Cash, Cash Equivalents and Marketable SecuritiesOur total cash, cash equivalents and marketable securities decreased to $9.8 billion as of September 30, 2026 as compared to $12.3 billion as of December 31, 2025 primarily due to $9.0 billion net cash used to acquire Crinetics and repurchases of our common stock pursuant to our share repurchase program, partially offset by $4.5 billion borrowed pursuant to a term loan (the “2026 Term Loan”) executed in the third quarter of 2026 and cash flows provided by our operating activities.

549755851365

549755851366

Q3 2025

Q3 2026

December 31, 2025

September 30, 2026

Note: Charts above may not add due to rounding.

Business Updates

Marketed Products

Cystic Fibrosis

We expect that the number of people with CF taking our medicines will continue to grow through new approvals and

reimbursement agreements, treatment of younger patients, increased survival and expansion into additional geographies.

Recent progress in activities expanding our CF business is included below:

  • In the third quarter of 2026, we secured reimbursement for ALYFTREK in seven additional countries, bringing the

total number of countries where ALYFTREK is reimbursed to 32.

Sickle Cell Disease and Beta Thalassemia

  • In the third quarter of 2026, we recorded $99.2 million of CASGEVY product revenues, representing a 30% increase

compared to the second quarter of 2026 and a more than 400% increase compared to the third quarter of 2025.

  • The U.S. Food and Drug Administration (the “FDA”) approved CASGEVY in children two years of age and older

with SCD or TDT, making it the first genetic therapy for SCD and TDT indicated for children as young as two years

of age. Since approval, multiple children have initiated treatment.

  • In October, the United Arab Emirates and Kingdom of Bahrain approved CASGEVY for the treatment of children 2

years of age and older, and the United Kingdom approved CASGEVY for the treatment of children 5 years of age

and older. We have completed regulatory submissions in the Kingdom of Saudi Arabia (“Saudi Arabia”) for the

treatment of children with SCD or TDT.

Acute Pain

  • In the third quarter of 2026, more than 750,000 prescriptions were filled for JOURNAVX across the hospital and

retail settings, representing a more than 40% increase compared to the second quarter of 2026 and more than four

times the 170,000 JOURNAVX prescriptions that were filled in the third quarter of 2025.

  • In the third quarter of 2026, we recorded $58.3 million of JOURNAVX product revenues, representing an 18%

increase since the second quarter of 2026, and nearly tripling the $19.6 million of JOURNAVX product revenues in

the third quarter of 2025.

Acromegaly

  • PALSONIFY (paltusotine) is a first-in-class, small molecule, once-daily oral somatostatin receptor type 2 agonist

approved in the U.S. for the treatment of adults with acromegaly who had an inadequate response to surgery or for

whom surgery is not an option. Acromegaly is a rare and debilitating condition caused by a benign pituitary tumor

that secretes excess growth hormone. There are an estimated 12,000 adults with acromegaly in the U.S. for whom

PALSONIFY is an option.

  • We recorded $10.1 million of PALSONIFY revenue in September 2026, following the closing of the Crinetics

Acquisition on September 1, 2026.

  • More than 245 million individuals have access to PALSONIFY, representing approximately 80% of U.S. covered

lives.

  • An estimated 3,200 endocrinologists treat the majority of people with acromegaly in the U.S. As of the end of the

third quarter of 2026, approximately 500 of those target specialty endocrinologists are prescribing PALSONIFY.

  • Among patients starting or switching therapy, PALSONIFY has the leading brand share at more than 40%.

  • PALSONIFY was approved in the European Union in April 2026. We expect to begin launches in European markets

in the second half of 2027. The regulatory submission for PALSONIFY in Japan was completed in April 2026, and

the Ministry of Health, Labor and Welfare (the “MHLW”) has granted orphan drug designation in Japan.

Pipeline

We continue to advance a diversified pipeline of potentially transformative medicines for serious diseases utilizing a

range of modalities. Recent and anticipated progress in activities supporting these efforts is included below:

Cystic Fibrosis

  • We have initiated global regulatory submissions for ALYFTREK for the treatment of children with CF two to five

years of age.

Acute and Peripheral Neuropathic Pain

  • We expect to complete enrollment in both Phase 3 clinical trials evaluating suzetrigine in diabetic peripheral

neuropathy, a form of peripheral neuropathic pain, by the end of 2026 and expect to share results in mid-2027.

IgA Nephropathy and Other B Cell-Mediated Diseases

  • We are developing povetacicept, a dual inhibitor of B cell activating factor (“BAFF”) and a proliferation-inducing

ligand (“APRIL”) cytokines, for multiple diseases. Povetacicept represents a potentially best-in-class approach to

control B cell activity in IgAN.

  • The biologics license application for accelerated approval of povetacicept for adults with IgAN is under priority

review by the FDA, with an assigned PDUFA target action date of November 30, 2026. If approved, povetacicept

will become the first commercialized therapy in our emerging nephrology franchise.

  • Povetacicept is under review for accelerated approval for adults with IgAN in Saudi Arabia, and the Saudi Food and

Drug Authority has granted Breakthrough designation to povetacicept.

  • Povetacicept represents a potentially best-in-class approach to control B cell activity in primary membranous

nephropathy (“pMN”), another B cell-mediated disease. We are enrolling and dosing patients in the Phase 3 portion

of the OLYMPUS Phase 2/3 pivotal trial evaluating povetacicept in people with pMN.

APOL1-Mediated Kidney Disease

  • Inaxaplin is our small molecule for the treatment of APOL1-mediated kidney disease (“AMKD”). We have

completed full enrollment in the AMPLITUDE pivotal clinical trial evaluating inaxaplin.

  • We are on track to conduct the pre-planned interim analysis for potential U.S. accelerated approval once the interim

analysis cohort has been treated for 48 weeks and to share data from the interim analysis in early 2027.

Rare Endocrine Disorders

  • We are developing atumelnant, a once-daily oral adrenocorticotropic hormone (“ACTH”) receptor antagonist, for

the treatment of classic congenital adrenal hyperplasia (“CAH”), which affects approximately 17,000 people in the

U.S. Classic CAH is a rare, chronic, genetic condition in which the adrenal glands are unable to make enough

cortisol. Current therapies force a choice between androgen control and steroid burden, representing a significant

unmet need.

  • The Phase 3 clinical trial evaluating atumelnant in adults with CAH is a global, 32-week, randomized, double blind,

placebo-controlled trial of 150 people. Enrollment and dosing are well underway, and we expect to complete

enrollment in the trial in the first quarter of 2027. The FDA, the European Medicines Agency, and the MHLW in

Japan have granted Orphan Drug designation to atumelnant in CAH.

  • Atumelnant has demonstrated therapeutic potential in people with ACTH-dependent Cushing’s syndrome, another

serious endocrine disease, which affects more than 10,000 people in the U.S. We have initiated a Phase 2/3 clinical

trial evaluating atumelnant in people with ACTH-dependent Cushing’s syndrome. The FDA has granted Orphan

Drug designation to atumelnant in ACTH-dependent Cushing’s syndrome.

Type 1 Diabetes

  • We are enrolling and dosing patients in a Phase 1/2 clinical trial to evaluate the safety and efficacy of VX-017 in

people with type 1 diabetes (“T1D”). VX-017 is an allogeneic, stem cell-derived, fully differentiated islet cell

therapy designed to treat the targeted patient population with T1D regardless of blood type.

  • Given the rapid progress of VX-017, we have decided to focus on accelerating the development of VX-017, which

has the potential to reach more people than zimislecel, which is designed for people with blood types A or A/B only.

We expect to advance VX-017 into pivotal development in 2027. The FDA has granted Fast Track designation to

VX-017.

Investment in External Innovation

  • In September, we completed the Crinetics Acquisition as described below.

Our Business Environment

In the first nine months of 2026, our total product revenues came primarily from the sale of our medicines for the

treatment of CF. Our CF strategy involves continuing to develop and obtain approval and reimbursement for treatment

regimens that will provide benefits to all people with CF and increasing the number of people with CF eligible and able to

receive our medicines. Outside of CF, we continue to advance the commercialization of CASGEVY for the treatment of SCD

and TDT, and JOURNAVX for the treatment of acute pain. We added PALSONIFY for the treatment of acromegaly to our

commercial portfolio in the third quarter of 2026 through the Crinetics Acquisition, and we are preparing for a potential

launch of povetacicept for the treatment of IgAN. In addition, we are advancing our pipeline of product candidates for the

treatment of serious diseases outside of CF, SCD, TDT, acute pain, and acromegaly.

Our strategy is to combine transformative advances in the understanding of causal human biology and the science of

therapeutics to discover and develop innovative medicines. This approach includes advancing multiple compounds or

therapies from each program, spanning multiple modalities, into early clinical trials to obtain patient data that can inform

selection of the most promising therapies for later-stage development, as well as to inform discovery and development

efforts. We aim to serially innovate in our disease areas of interest and follow our first-in-class therapies with potential best-

in-class candidates to provide durable clinical and commercial success.

In pursuit of new product candidates and therapies in specialty markets, we invest in research and development. We

believe that pursuing research in diverse areas allows us to balance the risks inherent in product development and may

provide product candidates that will form our pipeline in future years. To supplement our internal research programs, we

acquire technologies and programs and collaborate with biopharmaceutical and technology companies, leading academic

research institutions, government laboratories, foundations and other organizations, as needed, to advance research in our

areas of therapeutic interest and to access technologies needed to execute on our strategy.

Discovery and development of a new pharmaceutical or biological product is a difficult and lengthy process that requires

significant financial resources along with extensive technical and regulatory expertise. Across the industry, most potential

drug or biological products never progress into development, and most products that advance into development never receive

marketing approval. Our investments in product candidates are subject to considerable risks. We closely monitor our research

and development activities, and frequently evaluate our pipeline programs in light of new data and scientific, business and

commercial insights, with the objective of balancing risk and potential. This process can result in rapid changes in focus and

priorities as new information becomes available and as we gain additional understanding of our ongoing programs and

potential new programs, as well as those of our competitors. In addition, our product candidates must satisfy rigorous

standards of safety and efficacy before they can be approved for sale by regulatory authorities. Our analysis of data obtained

from nonclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could

delay, limit or prevent regulatory approval.

Our business also requires ensuring appropriate manufacturing and supply of our products. As we advance our product

candidates through clinical development toward commercialization and market and sell our approved products, we build and

maintain our supply chain and quality assurance resources. We rely on a global network of third parties, including some in

China, and our internal capabilities to manufacture and distribute our products for commercial sale and post-approval clinical

trials and to manufacture and distribute our product candidates for clinical trials. In addition to establishing supply chains for

each newly approved product, we adapt our supply chain for existing products to include additional formulations or to

increase scale of production for existing products as needed. The processes for biological and cell and genetic therapies can

be more complex than those required for small molecule drugs and require additional investments in different systems,

equipment, facilities and expertise. We are focused on ensuring the stability of the supply chains for our current products, as

well as for our pipeline programs.

Sales of our products depend, to a large degree, on the extent to which our products are reimbursed by third-party payors,

such as government health programs, commercial insurance and managed health care organizations. Reimbursement for our

products, including our potential pipeline therapies, cannot be assured and may take significant periods of time to obtain. We

dedicate substantial management and other resources to obtain and maintain appropriate levels of reimbursement for our

products from third-party payors, including governmental organizations in the U.S. and ex-U.S. markets. In the U.S., we

work with government and commercial payors to obtain and maintain appropriate levels of reimbursement for our medicines.

In ex-U.S. markets, we seek government reimbursement for our medicines on a country-by-country or region-by-region, as

required. This is necessary for each new medicine, as well as for label expansions for our current medicines. We expect to

continue to focus significant resources to expand and maintain reimbursement for our CF medicines, CASGEVY,

JOURNAVX, PALSONIFY, and, ultimately, our pipeline therapies, in U.S. and ex-U.S. markets.

Strategic Transactions

Acquisitions

As part of our business strategy, we seek to license or acquire technologies, products, product candidates and businesses

that are aligned with our corporate and research and development strategies and complement and advance our ongoing

research and development efforts. We have acquired multiple biotechnology companies over the last several years and expect

to continue to identify and evaluate such opportunities. The accounting for an acquisition can vary significantly based on

whether we conclude the relevant transaction represents a business combination or asset acquisition.

In 2024, we acquired Alpine Immune Sciences, Inc. (“Alpine”) and its lead molecule, povetacicept, for approximately

$5.0 billion. Povetacicept, has shown potential to treat multiple diseases or conditions and become a pipeline-in-a-product.

We accounted for the Alpine transaction as an asset acquisition because povetacicept represented substantially all of the fair

value of the gross assets that we acquired. As a result, $4.4 billion of the fair value attributed to povetacicept was expensed as

AIPR&D in 2024.

In September 2026, we acquired Crinetics, a publicly traded biotechnology company focused on discovering,

developing, and commercializing novel therapeutics for endocrine diseases and endocrine-related tumors, for $85.00 per

share in cash, equaling a total equity value of $10.0 billion, or $9.0 billion net of cash, cash equivalents and marketable

securities acquired. We funded the acquisition with our cash and cash equivalents and marketable securities, and $4.5 billion

of proceeds from the 2026 Term Loan. We have accounted for the Crinetics Acquisition as a business combination, which

resulted in $8.1 billion of additional intangible assets, as well as other assets acquired and liabilities assumed, recorded on our

condensed consolidated balance sheet. Please refer to Note C, “Business Combination,” for further information.

Collaboration and In-Licensing Arrangements

We enter into arrangements with third parties, including collaboration and licensing arrangements, for the development,

manufacture and commercialization of products, product candidates and other technologies that have the potential to

complement our ongoing research and development efforts.

We have collaboration agreements with a number of companies, including CRISPR Therapeutics AG (“CRISPR”) and

Entrada Therapeutics, Inc. (“Entrada”).

Generally, when we in-license a technology or product candidate, we make upfront payments to the collaborator, assume

the costs of the program and/or agree to make contingent payments, which could consist of milestone, royalty and option

payments. Most of these collaboration payments are expensed as AIPR&D because they were primarily attributable to

acquired in-process research and development for which there was no alternative future use. However, depending on many

factors, including the structure of the collaboration, the stage of development of the acquired technology, the significance of

the in-licensed product candidate to the collaborator’s operations and the other activities in which our collaborators are

engaged, the accounting for these transactions can vary significantly. We expect to continue to identify and evaluate

collaboration and licensing opportunities that may be similar to or different from the collaborations and licenses that we have

engaged in previously.

Acquired In-Process Research and Development Expenses

In the first nine months of 2026 and 2025, our AIPR&D included $62.5 million and $76.5 million, respectively, related

to upfront, contingent milestone, or other payments pursuant to our business development transactions, including the asset

acquisitions, collaborations, and licenses of third-party technologies described above. Please refer to Note B, “Collaboration,

License and Other Arrangements,” for further information regarding our asset acquisitions, collaborations and in-license

agreements.

Out-licensing Arrangements

We also have out-licensed certain development programs to collaborators who are leading the development or

commercialization of these programs, either globally or within certain geographic regions.

In January 2025 and June 2025, we entered into agreements with Zai Lab Limited (“Zai”) and Ono Pharmaceuticals Co.,

Ltd (“Ono”), respectively, for the development and commercialization of povetacicept in various Asian markets. Zai licensed

povetacicept for mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore, while Ono licensed

povetacicept for Japan and South Korea. Zai and Ono will help advance povetacicept clinical trials, and will be responsible

for obtaining marketing authorizations and commercialization activities, if povetacicept becomes an approved product, in

their licensed territories. We are eligible to receive certain future milestone payments and tiered royalties on future net sales

of povetacicept in these regions.

RESULTS OF OPERATIONS

Total Revenues

Three Months Ended September 30,Nine Months Ended September 30,
20262025Change20262025Change
(in millions, except percentages)
TRIKAFTA/KAFTRIO$2,436.9$2,653.6(8)%$7,288.8$7,740.2(6)%
ALYFTREK705.8247.0186%1,703.8457.7272%
Other CF product revenues (1)130.5139.3(6)%403.5488.3(17)%
Total CF product revenues, net3,273.23,039.98%9,396.18,686.28%
CASGEVY99.216.9487%218.561.5255%
JOURNAVX58.319.6197%136.932.9316%
PALSONIFY10.1—**10.1—**
Product revenues, net3,440.83,076.412%9,761.68,780.611%
Other revenues——**—30.7**
Total revenues$3,440.8$3,076.412%$9,761.6$8,811.311%
(1) Include KALYDECO, ORKAMBI and SYMDEKO/SYMKEVI.** Not meaningful

Product Revenues, Net

In the third quarter and first nine months of 2026, our net product revenues increased 12% and 11%, as compared to the

third quarter and first nine months of 2025, respectively, primarily due to continued performance of our CF therapies and

growth from diversification into additional disease areas.

Other Revenues

Other revenues were $30.7 million in the nine months ended September 30, 2025, which included $20.6 million and

$10.0 million related to upfront payments received from our collaboration agreements with Ono Pharmaceuticals Co., Ltd.

and Zai Lab Limited, respectively, in the first half of 2025.

Total Revenues by Geographic Location

Our total revenues from the U.S. and from ex-U.S. markets were as follows:

Three Months Ended September 30,Nine Months Ended September 30,
20262025Change20262025Change
(in millions, except percentages)
United States$2,169.1$1,976.310%$6,001.4$5,488.09%
ex-U.S.1,271.71,100.116%3,760.23,323.313%
Total revenues$3,440.8$3,076.412%$9,761.6$8,811.311%

In the third quarter and first nine months of 2026, our U.S. total revenues increased 10% and 9%, as compared to the

third quarter and first nine months of 2025, respectively, primarily due to continued strong patient demand, including from

new initiations of ALYFTREK, and higher realized net prices in CF, and contributions from CASGEVY, JOURNAVX and

PALSONIFY.

In the third quarter and first nine months of 2026, our ex-U.S. total revenues increased 16% and 13%, as compared to the

third quarter and first nine months of 2025, respectively, primarily due to strong CF performance across multiple

geographies, including ALYFTREK uptake, increased CASGEVY product revenues, and favorable impacts from foreign

exchange.

Operating Costs and Expenses

Three Months Ended September 30,Nine Months Ended September 30,
20262025Change20262025Change
(in millions, except percentages)
Cost of sales$526.1$414.827%$1,408.1$1,185.319%
Research and development expenses1,320.6977.735%3,276.02,935.812%
Acquired in-process research and development expenses40.654.5(26)%62.576.5(18)%
Selling, general and administrative expenses844.1445.190%1,920.01,266.152%
Intangible asset impairment charge——**—379.0**
Change in fair value of contingent consideration(3.5)(1.9)**(2.9)1.2**
Total costs and expenses$2,727.9$1,890.244%$6,663.7$5,843.914%
** Not meaningful

Cost of Sales

Our cost of sales primarily consists of third-party royalties payable on net sales of our CF products as well as the cost of

producing inventories. In the third quarter and first nine months of 2026, our cost of sales also included $15.3 million of

PALSONIFY intangible asset amortization expense and $5.4 million of PALSONIFY acquired inventory step-up expense

related to the month of September. In future quarters, the amount of intangible asset amortization expense and acquired

inventory step-up expenses will increase.

Our cost of sales as a percentage of our net product revenues increased to 15.3% and 14.4% in the third quarter and first

nine months of 2026, respectively, as compared to 13.5% in each of the third quarter and first nine months of 2025, as a result

of changes in product mix and the intangible asset amortization and acquired inventory step-up expense described above,

partially offset by a lower blended royalty rate for our CF medicines.

Pursuant to our agreement (the “CFF Agreement”) with the Cystic Fibrosis Foundation (the “CFF”), our tiered third-

party royalties on sales of ALYFTREK, TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, KALYDECO, and ORKAMBI,

calculated as a percentage of net sales, range from the single digits to the sub-teens, with lower royalties on sales of

ALYFTREK and TRIKAFTA/KAFTRIO than for our other products. The royalty burden associated with TRIKAFTA/

KAFTRIO is 9.33%, and our position is that the royalty burden associated with ALYFTREK is 4%. On October 10, 2025,

Royalty Pharma plc (“RP”), the third party to whom the CFF assigned its rights (and the CFF, which remains a party to the

CFF Agreement), initiated a confidential arbitration alleging the royalty burden on ALYFTREK is approximately 8%. RP is

seeking a declaratory judgment regarding the royalty burden on ALYFTREK as well as alleged unpaid royalties and other

alleged damages available under the CFF Agreement or applicable law, costs, expenses, attorneys’ fees, and interest. We

believe RP’s position is contrary to the plain terms of the CFF Agreement and intend to vigorously defend our position under

the CFF Agreement.

Research and Development Expenses

Three Months Ended September 30,Nine Months Ended September 30,
20262025Change20262025Change
(in millions, except percentages)
Research expenses$229.0$210.09%$641.3$625.43%
Development expenses1,091.6767.742%2,634.72,310.414%
Total research and development expenses$1,320.6$977.735%$3,276.0$2,935.812%

Research Expenses

Three Months Ended September 30,Nine Months Ended September 30,
20262025Change20262025Change
(in millions, except percentages)
Research Expenses:
Salary and benefits$52.0$49.65%$158.5$155.82%
Stock-based compensation expense19.528.0(30)%61.972.8(15)%
Compensation expense for cash-settled unvested Crinetics equity awards30.2—**30.2—**
Outsourced services and other direct expenses63.372.2(12)%201.1216.3(7)%
Infrastructure costs64.060.26%189.6180.55%
Total research expenses$229.0$210.09%$641.3$625.43%
** Not meaningful

Our research expenses include investment in our pipeline, including our cell and genetic therapy capabilities. Our

research expenses increased in the third quarter and first nine months of 2026 as compared to the third quarter and first nine

months of 2025, primarily due to compensation expense associated with cash-settled unvested equity awards related to the

Crinetics Acquisition. We expect to continue to invest in our research programs with a focus on creating transformative

medicines for serious diseases.

Development Expenses

Three Months Ended September 30,Nine Months Ended September 30,
20262025Change20262025Change
(in millions, except percentages)
Development Expenses:
Salary and benefits$222.2$182.222%$628.9$565.411%
Stock-based compensation expense82.588.0(6)%246.2242.91%
Compensation expense for cash-settled unvested Crinetics equity awards235.3—**235.3—**
Outsourced services and other direct expenses409.2364.712%1,103.11,116.9(1)%
Infrastructure costs142.4132.87%421.2385.29%
Total development expenses$1,091.6$767.742%$2,634.7$2,310.414%
** Not meaningful

Our development expenses increased by 42% and 14% in the third quarter and first nine months of 2026 as compared to

the third quarter and first nine months of 2025, respectively, primarily due to $235.3 million of compensation expense

associated with cash-settled unvested equity awards related to the Crinetics Acquisition, which we recorded in the third

quarter of 2026, and increased outsourced services and other direct expenses. Our outsourced services and other direct

expenses were lower as compared to the first nine months of 2025 due to the discontinuation of certain clinical programs

during 2025.

As we have advanced our pipeline, we have invested in internal headcount and infrastructure to support multiple mid-

and late-stage clinical development programs, including our povetacicept, T1D, peripheral neuropathic pain and AMKD

programs. We expect to continue to invest in these programs, launch new products and advance our pipeline going forward.

Our research and development expenses include internal and external costs incurred for research and development of our

products and product candidates. We assign external costs of services provided to us by clinical research organizations and

other outsourced research by individual program. Our internal costs include salary and benefits, stock-based compensation

expense, laboratory supplies and other direct expenses and infrastructure costs, the majority of which are not assigned to

individual products or product candidates. Our stock-based compensation expenses, including those recorded as research and

development expenses, have historically fluctuated and are expected to continue to fluctuate from one period to another

primarily due to changes in the probability of achieving milestones associated with our performance-based awards.

Acquired In-Process Research and Development Expenses

Three Months Ended September 30,Nine Months Ended September 30,
20262025Change20262025Change
(in millions, except percentages)
Acquired in-process research and development expenses$40.6$54.5(26)%$62.5$76.5(18)%

AIPR&D in the third quarter and first nine months of 2026 and 2025 included various upfront and milestone payments

related to our collaboration and in-licensing arrangements. Our AIPR&D has historically fluctuated, and is expected to

continue to fluctuate, from one period to another due to upfront, contingent milestone, and other payments pursuant to our

existing and future business development transactions, including collaborations, licenses of third-party technologies, and

asset acquisitions.

Selling, General and Administrative Expenses

Three Months Ended September 30,Nine Months Ended September 30,
20262025Change20262025Change
(in millions, except percentages)
Selling, general and administrative expenses$844.1$445.190%$1,920.0$1,266.152%

In the third quarter and first nine months of 2026, our selling, general and administrative expenses increased by 90% and

52% as compared to the third quarter and first nine months of 2025, respectively, primarily due to a total of $203.0 million of

compensation expense for cash-settled unvested equity awards and transaction costs related to the Crinetics Acquisition in the

third quarter of 2026, increased internal headcount and commercial investment to support JOURNAVX and the anticipated

launch of povetacicept in IgAN. We expect to continue to invest in our commercialization capabilities in support of our

current and future product launches.

Intangible Asset Impairment Charge

In the first quarter of 2025, based on results from a Phase 1/2 clinical trial evaluating our VX-264 clinical program in

patients with T1D, we concluded that VX-264 will not be advancing further in clinical development. Based on this event, we

performed an interim impairment test on the fair value of our VX-264 indefinite-lived in-process research and development

asset. As a result, we recorded a full intangible asset impairment charge of $379.0 million associated with VX-264 in the first

quarter of 2025.

Non-Operating Income (Expense), Net

Interest Income

Our interest income decreased to $118.4 million in the third quarter of 2026 as compared to $125.7 million in the third

quarter of 2025, primarily due to reduced cash, cash equivalents and marketable securities following the Crinetics Acquisition

and decreased market rates. Our interest income decreased to $360.1 million in the first nine months of 2026 as compared to

$369.0 million in the first nine months of 2025, primarily due to decreased market rates partially offset by increased overall

cash, cash equivalents and marketable securities. We expect our future interest income to decrease as a result of our

decreased cash, cash equivalents and marketable securities following the Crinetics acquisition.

Interest Expense

Our interest expense increased to $36.0 million and $42.3 million in the third quarter and first nine months of 2026,

respectively, as compared to our interest expense of $3.3 million and $10.0 million in the third quarter and first nine months

of 2025, respectively, due to $4.5 billion that we borrowed on September 1, 2026 pursuant to the 2026 Term Loan and fees

associated with a debt commitment letter that preceded the 2026 Term Loan. Due to the amount that we borrowed in

September 2026, we expect our future interest expense to increase.

Other Income (Expense), Net

Other income (expense), net was expense of $11.9 million and income of $12.4 million in the third quarter and first nine

months of 2026, respectively, and were expenses of $9.8 million and $14.2 million in the third quarter and first nine months

of 2025, respectively. Our other income (expense), net in the third quarter and first nine months of 2026 was primarily due to

a realized gain associated with one of our strategic investments partially offset by realized losses on marketable securities

sales. Our other income (expense), net in the third quarter and first nine months of 2025 was primarily due to net unrealized

and realized gains and losses resulting from changes in the fair value of certain of our strategic equity investments and net

foreign currency exchange gains and losses.

Income Taxes

Our effective tax rate fluctuates from period to period due to the global nature of our operations. The factors that most

significantly impact our effective tax rate include changes in tax laws, excess tax benefits related to stock-based

compensation, variability in the amount and allocation of our taxable earnings among multiple jurisdictions, the amount and

characterization of our research and development expenses, the levels of certain deductions and credits, adjustments to the

value of our uncertain tax positions, acquisitions and third-party collaboration and licensing transactions.

Our effective tax rate of 18.8% in the first nine months of 2026 was lower than the U.S. statutory rate, primarily due to a

benefit from a research and development tax credit study that was completed in the third quarter of 2026, and excess tax

benefits related to stock-based compensation. Our effective tax rate of 16.6% in the first nine months of 2025 was lower than

the U.S. statutory rate, primarily due to a benefit from a research and development tax credit study that was completed in the

third quarter of 2025, excess tax benefits related to stock-based compensation, and increased utilization of foreign tax credits,

partially offset by changes in uncertain tax positions.

LIQUIDITY AND CAPITAL RESOURCES

The following table summarizes the components of our financial condition as of September 30, 2026 and December 31,

2025:

As of September 30, 2026As of December 31, 2025Change
(in millions, except percentages)
Cash, cash equivalents and marketable securities:
Cash and cash equivalents$4,979.3$5,084.8
Marketable securities1,324.01,523.3
Long-term marketable securities3,517.95,712.3
Total cash, cash equivalents and marketable securities$9,821.2$12,320.4(20)%
Working Capital:
Total current assets$11,686.3$11,201.04%
Total current liabilities(5,000.3)(3,861.2)30%
Total working capital$6,686.0$7,339.8(9)%

Working Capital

As of September 30, 2026, total working capital was $6.7 billion, which represented a decrease of $653.8 million, or 9%,

compared to December 31, 2025, primarily due to $1.0 billion of short-term debt related to the 2026 Term Loan and

decreased cash, cash equivalents and short-term marketable securities following the Crinetics Acquisition, partially offset by

increased inventories as a result of the Crinetics Acquisition.

Cash Flows

Nine Months Ended September 30,
20262025
(in millions)
Net cash provided by (used in):
Operating activities$3,196.6$3,133.4
Investing activities$(6,578.3)$(657.3)
Financing activities$3,331.4$(2,184.1)

Operating Activities

Cash provided by operating activities increased to $3.2 billion in the first nine months of 2026, as compared to $3.1

billion in the first nine months of 2025, primarily due to less cash used for income taxes and inventory purchases, partially

offset by increased cash used to satisfy product revenue accruals.

Investing Activities

Cash used in investing activities was $6.6 billion in the first nine months of 2026, primarily related to $9.1 billion paid to

acquire Crinetics, net of cash and cash equivalents acquired, partially offset by $2.8 billion net sales and maturities of

available-for-sale debt securities. Cash used in investing activities was $657.3 million in the first nine months of 2025,

primarily related to net purchases of available-for-sale debt securities and purchases of property and equipment.

Financing Activities

Cash provided by financing activities was $3.3 billion in the first nine months of 2026, primarily due to $4.5 billion we

borrowed pursuant to our 2026 Term Loan partially offset by repurchases of our common stock pursuant to our share

repurchase programs. Cash used in financing activities was $2.2 billion in the first nine months of 2025, primarily related to

repurchases of our common stock pursuant to our share repurchase programs and payments in connection with common stock

withheld for employee tax obligations.

Sources and Uses of Liquidity

We intend to rely on our existing cash, cash equivalents and current marketable securities together with our operating

profitability as our primary source of liquidity. We expect that cash flows from our product sales together with our cash, cash

equivalents and current marketable securities will be sufficient to fund our operations for at least the next twelve months.

The adequacy of our available funds to meet our future operating and capital requirements will depend on many factors,

including our future sales of currently marketed products, and the potential introduction of one or more new product

candidates to the market, our business development activities, and the number, breadth and cost of our research and

development programs.

Credit Facilities & Financing Strategy

In July 2026, we entered into the $4.5 billion 2026 Term Loan to finance a portion of the Crinetics Acquisition. We

borrowed the entire $4.5 billion in September 2026. Amounts due under the 2026 Term Loan are described below and can be

prepaid without penalty. We may also borrow up to a total of $500.0 million pursuant to a revolving credit facility that we

entered into in July 2026 (the “2026 Revolver”) and could repay and reborrow amounts under this revolving credit agreement

without penalty. Subject to certain conditions, we could request that the borrowing capacity be increased by an additional

$500.0 million, for a total of $1.0 billion. Covenants in the 2026 Term Loan and the 2026 Revolver could prohibit or limit

our ability to access these sources of liquidity.

Future Capital Requirements

We have significant future capital requirements, including:

  • We are required to repay the $4.5 billion that we borrowed under the 2026 Term Loan as follows: $1.0 billion in

August 2027, $1.0 billion in September 2028, and $2.5 billion in August 2029.

  • Expected operating expenses to conduct research and development activities, manufacture and commercialize our

existing and future products, and to operate our organization.

  • Cash that we pay for income taxes.

  • Royalties we pay related to sales of our CF products.

  • Facility, operating and finance lease obligations.

  • Firm purchase obligations related to our supply and manufacturing processes.

In addition, other potential significant future capital requirements may include:

  • We have entered into certain agreements with third parties that include the funding of certain research, development,

manufacturing and commercialization efforts. Certain of our transactions, including collaborations, licensing

arrangements, and asset acquisitions, include the potential for future milestone and royalty payments by us upon the

achievement of pre-established developmental and regulatory targets and/or commercial targets. Other transactions

include the potential for future lease-related expenses and other costs. Our obligation to fund these research and

development and commercialization efforts and to pay these potential milestones, expenses and royalties is

contingent upon continued involvement in the programs and/or the lack of any adverse events that could cause their

discontinuance. We may enter into additional agreements, including acquisitions, collaborations, licensing

arrangements and equity investments, which require additional capital.

  • To the extent we borrow amounts under the 2026 Revolver, we would be required to repay any outstanding principal

amounts in July 2031.

  • As of September 30, 2026, we had $2.5 billion remaining available under the share repurchase program that our

Board of Directors authorized in May 2025. The program does not have an expiration date and can be discontinued

at any time. We expect to fund the program through a combination of cash on hand and cash generated by

operations.

Other than the amounts borrowed under the 2026 Term Loan, there have not been any material changes to our future

capital requirements disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed

with the Securities and Exchange Commission, or SEC, on February 13, 2026.

We may also raise additional capital by borrowing under credit agreements, through public offerings or private

placements of our securities, or securing new collaborative agreements or other methods of financing. We will continue to

manage our capital structure and will consider all financing opportunities, whenever they may occur, that could strengthen

our long-term liquidity profile. There can be no assurance that any such financing opportunities will be available on

acceptable terms, if at all.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our discussion and analysis of our financial condition and results of operations are based upon our condensed

consolidated financial statements prepared in accordance with generally accepted accounting principles in the U.S. The

preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported

amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated

financial statements and the reported amounts of revenues and expenses during the reported periods. These items are

monitored and analyzed by management for changes in facts and circumstances, and material changes in these estimates

could occur in the future. Changes in estimates are reflected in reported results for the period in which the change occurs. We

base our estimates on historical experience and various other assumptions that we believe to be reasonable under the

circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be

substantially accurate. During the nine months ended September 30, 2026, there were no material changes to our critical

accounting policies as reported in our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed

with the SEC on February 13, 2026.

RECENT ACCOUNTING PRONOUNCEMENTS

For a discussion of recent accounting pronouncements, please refer to Note A, “Basis of Presentation and Accounting

Policies.”

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Other than the update below, information required by this item is incorporated by reference from the discussion in Part

II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the year

ended December 31, 2025, which was filed with the SEC on February 13, 2026.

In the third quarter of 2026, we entered into the 2026 Term Loan and 2026 Revolver described in Note M,

“Commitments and Contingencies.” Loans under these agreements bear interest, at our option, at a base rate or a SOFR-based

rate, in each case, plus an applicable margin based on our consolidated leverage ratio. We do not believe that changes in

interest rates related to the 2026 Term Loan or 2026 Revolver would have a material effect on our consolidated financial

statements, and we do not currently use hedge instruments to manage our exposure to these interest rate changes. As of

September 30, 2026, we had $4.5 billion outstanding under the 2026 Term Loan that we borrowed on September 1, 2026 and

no principal or interest outstanding under the 2026 Revolver. For amounts borrowed under the 2026 Term Loan, we estimate

that a 1% unfavorable change in interest rates would result in a $45.0 million increase in our interest expense for the first year

subsequent to September 1, 2026, with declining exposure thereafter.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management (under the supervision and with the participation of our chief executive officer and chief financial

officer), after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and

15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly

Report on Form 10-Q, has concluded that, based on such evaluation, as of September 30, 2026 our disclosure controls and

procedures were effective and designed to provide reasonable assurance that the information required to be disclosed is

recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. In designing

and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no

matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives,

and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible

controls and procedures.

Changes in Internal Controls Over Financial Reporting

On September 1, 2026, we completed the Crinetics Acquisition, which was accounted for as a business combination. As

a result, Crinetics operations have been included in our condensed consolidated statements of income since September 1,

While we are currently in the process of evaluating and integrating Crinetics' historical internal controls over financial

reporting with ours, no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f)

under the Securities Exchange Act of 1934, as amended) occurred during the three months ended September 30, 2026 that

have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. Other Informatio****n

Item 1. Legal Proceedings

Other than as described in Part I—Note M, “Commitments and Contingencies,” to our condensed consolidated financial

statements, we are not currently subject to any material legal proceedings.

Item 1A. Risk Factors

The information presented below supplements the risk factors set forth in Part I, Item 1A. “Risk Factors” of our Annual

Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 13, 2026.

We may be unable to successfully integrate Crinetics’ business, or realize the potential commercial benefits of the

strategic acquisition, which could adversely affect our business and financial condition.

Our inability to successfully integrate the Crinetics business could have a material adverse effect on our business. Our

realization of the value from the Crinetics Acquisition relies on successful integration of its operations. We may not be able

to integrate Crinetics’ business successfully into our existing business, make Crinetics’ business profitable, retain key

employees or realize anticipated cost savings or synergies, if any, from the acquisition, which could adversely affect our

business and financial condition. Further, our ongoing business may be disrupted, and our management's attention may be

diverted by integration activities. In addition, the anticipated benefits of the Crinetics Acquisition depend on revenues from

PALSONIFY and the commercial potential of atumelnant. If PALSONIFY does not achieve the sales, market acceptance, or

other commercial performance we expect, if development of atumelnant is delayed or terminated, or if we fail to obtain

approval or fail to successfully commercialize atumelnant, we may not realize the expected revenue growth or income

contribution from these assets on the anticipated timeline, or at all, which could adversely affect our business and financial

condition.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q and, in particular, our Management’s Discussion and Analysis of Financial

Condition and Results of Operations set forth in Part I, Item 2, contain a number of forward-looking statements. Forward-

looking statements are not purely historical and may be accompanied by words such as “anticipates,” “may,” “forecasts,”

“expects,” “intends,” “plans,” “potentially,” “believes,” “seeks,” “estimates,” and other words and terms of similar meaning.

Such statements may relate to:

  • our financial performance, including revenues, costs and expenses, taxes, and other gains and losses;

  • product development, including our development timelines, timing of data from our ongoing and planned clinical

trials, regulatory authority filings and other submissions for our therapies, including the potential to file for

accelerated approvals, and communications with regulatory authorities, including our expectations regarding the

FDA’s review of our biologics license application for accelerated approval of povetacicept with an assigned PDUFA

target action date of November 30, 2026;

  • our ability to continue to grow our CF business by increasing the number of people with CF eligible and able to

receive our medicines through new approvals, label extensions and reimbursement agreements, treatment of younger

patients, increased survival, and expansion into additional geographies;

  • our ability to continue to launch, commercialize and market our products, including the anticipated launch of

povetacicept for the treatment of IgAN, and our ability to obtain label expansions for existing therapies;

  • our ability to obtain and maintain adequate coverage, pricing, and reimbursement from third-party payors for our

products;

  • the data that will be generated by ongoing and planned clinical trials, preclinical and nonclinical studies, and the

ability to use that data to advance compounds, continue development or support regulatory filings, or accelerate

regulatory approval;

  • our plans to continue investing in our research and development programs, including anticipated timelines for our

programs, and our strategy to develop our pipeline programs, alone or with third party-collaborators;

  • our ability to use our research programs to identify and develop new product candidates to address serious diseases

and significant unmet medical needs;

  • our beliefs regarding the approximate patient populations for the disease areas on which we focus;

  • our expectations regarding Crinetics’ business and operations, the commercial potential of PALSONIFY and the

anticipated potential of atumelnant, and that Crinetics will contribute to the diversity of our pipeline and support our

long-term growth objectives;

  • plans for and prospects of our business development activities, including the potential benefits and therapeutic scope

of our collaborations, our ability to integrate and continue operations of acquired businesses, and our ability to

successfully capitalize on these opportunities;

  • the establishment, development and maintenance of collaborative relationships, including potential milestone

payments or other obligations, and other potential business development activities, including the identification of

potential collaborative partners or acquisition targets;

  • our plans to maintain and expand our global supply chains and manufacturing infrastructure and capabilities,

including for biologics, cell and gene therapies;

  • our ability to expand and protect our intellectual property portfolio and otherwise maintain exclusive rights to

products;

  • our expectations or beliefs regarding any legal proceedings in which we are involved, including any litigation,

arbitration or other similar proceedings involving our products, product candidates or activities;

  • potential fluctuations in foreign currency exchange rates and the effectiveness of our foreign currency management

program;

  • our expectations regarding cash generated by operations, our cash balance, cost of sales, interest income and interest

expenses;

  • our expectations regarding our provision for or benefit from income taxes and the utilization of our deferred tax

assets; and

  • our liquidity and our expectations regarding the possibility of raising additional capital.

Forward-looking statements are subject to certain risks, uncertainties, or other factors that are difficult to predict and

could cause actual events or results to differ materially from those indicated in any such statements. These risks,

uncertainties, and other factors include, but are not limited to, those described in our “Risk Factors” in Item 1A of our Annual

Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 13, 2026, and those

described from time to time in our future reports filed with the Securities and Exchange Commission.

Any such forward-looking statements are made on the basis of our views and assumptions as of the date of the filing and

are not estimates of future performance. Except as required by law, we undertake no obligation to publicly update any

forward-looking statements. The reader is cautioned not to place undue reliance on any such statements.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Repurchases of Equity Securities

In May 2025, our Board of Directors authorized a share repurchase program (our “Share Repurchase Program”),

pursuant to which we were authorized to repurchase up to $4.0 billion of our common stock. The Share Repurchase Program

does not have an expiration date and can be discontinued at any time.

The table set forth below shows repurchases of securities by us during the three months ended September 30, 2026 under

our Share Repurchase Program.

PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1)Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs (1)
July 1, 2026 to July 31, 2026218,272$487.40218,272$2,475,622,739
August 1, 2026 to August 31, 202632,271$477.6732,271$2,460,207,936
September 1, 2026 to September 30, 2026—$——$2,460,207,936
Total250,543$486.15250,543$2,460,207,936

(1) Under our Share Repurchase Program, we are authorized to purchase shares from time to time through open market or privately

negotiated transactions. Such purchases may be pursuant to Rule 10b5-1 plans or other means as determined by our management and

in accordance with the requirements of the Securities and Exchange Commission.

Item 5. Other Information

Rule 10b5-1 Trading Plans

Our policy governing transactions in our securities by our directors, officers, and employees permits our officers,

directors and employees to enter into trading plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934,

as amended. The following table describes the written plans for the sale of our securities adopted by our directors and officers

(as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) during the third quarter of 2026, each of which is

intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”). Other than as described in the

table below, none of our directors or officers adopted, modified or terminated a Trading Plan in the third quarter of 2026.

Name and TitleDate of Adoption of Trading PlanScheduled Expiration Date of Trading Plan (1)Maximum Shares Subject to Trading Plan
Kristen Ambrose SVP, Chief Accounting Officer8/06/20264/30/20275,422(2)
Sangeeta Bhatia Director8/13/20267/30/20271,189
Carmen Bozic EVP, Global Medicines Development and Medical Affairs, and Chief Medical Officer8/06/20267/30/202716,915(2)
Alan Garber Director8/27/20267/30/20275,320
Reshma Kewalramani Chief Executive Officer and President, Director8/5/202612/1/202747,800
Jeffrey Leiden Executive Chairman8/5/202611/4/202718,411
Joy Liu EVP, Chief Legal Officer8/21/20265/3/202720,764(2)
Bruce Sachs Director8/26/20267/20/20279,888
Nancy Thornberry Director8/15/20267/30/20272,571
Charles F. Wagner, Jr. EVP, Chief Operating & Financial Officer8/10/20267/30/202715,286
(1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.
(2) The maximum shares listed has not been reduced by the number of shares of common stock that will be withheld to satisfy tax withholding obligations at future vesting dates because such number of shares is not yet determinable.

Principal Accounting Officer

On October 30, 2026, the Company appointed Jonathan Oppenheim, our Vice President, Corporate Controller, as our

principal accounting officer, effective on February 15, 2027 (the “Effective Date”). On the Effective Date, Kristen Ambrose

will be appointed Senior Vice President, Global Business Operations and Transformation and will cease serving as our

principal accounting officer.

Jonathan Oppenheim, 56, has been our Vice President, Corporate Controller since August 2020. Mr. Oppenheim

previously served as Controller, US Business Unit at Takeda Pharmaceutical Company, a global biopharmaceutical company,

from January 2019 to August 2020. Prior to that, he served as Senior Director, Assistant Corporate Controller at Shire plc, a

biotechnology company, from November 2015 to January 2019, and Director, Technical Accounting at Thermo Fisher

Scientific Inc., a life sciences and clinical research company, from May 2010 to November 2015. Mr. Oppenheim received

his B.S. in Accounting from the University of Massachusetts Dartmouth and is a Certified Public Accountant.

There are no transactions involving the Company and Mr. Oppenheim that the Company would be required to report

pursuant to Item 404(a) of Regulation S-K. There is no arrangement or understanding between Mr. Oppenheim and any other

person pursuant to which Mr. Oppenheim was appointed as principal accounting officer.

Item 6. Exhibits

Exhibit NumberExhibit Description
10.1Revolving Credit Agreement, dated as of July 30, 2026, by and among Vertex Pharmaceuticals Incorporated, Bank of America, N.A., and other lenders party thereto.
10.2Term Loan Agreement, dated as of July 30, 2026, by and among Vertex Pharmaceuticals Incorporated, Bank of America, N.A., and other lenders party thereto.
10.3Employment Agreement, dated as of August 31, 2026, by and between Vertex Pharmaceuticals Incorporated and Jonathan Poole.*
10.4Change of Control Agreement, dated as of August 31, 2026, between Vertex Pharmaceuticals Incorporated and Jonathan Poole.*
31.1Certification of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
31.2Certification of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
32.1Certification of the Chief Executive Officer and the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.
101.INSXBRL Instance - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema
101.CALXBRL Taxonomy Extension Calculation
101.LABXBRL Taxonomy Extension Labels
101.PREXBRL Taxonomy Extension Presentation
101.DEFXBRL Taxonomy Extension Definition
104Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
*Management contract, compensatory plan or agreement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be

signed on its behalf by the undersigned thereunto duly authorized.

Vertex Pharmaceuticals Incorporated
November 3, 2026By:/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President, Chief Operating & Financial Officer (principal financial officer and duly authorized officer)